THE UPTAKE OF ADRENALINE BY THE RAT ISOLATED HEART

Organic Cation Transporters and Nongenomic Glucocorticoid Action

Corticosteroid hormones exert powerful influences on neuronal physiology and behavior by activating intracellular glucocorticoid receptors (GR) and mineralocorticoid receptors (MR), which act as ligand-gated transcription factors, altering gene expression. In addition to these genomic effects on physiology and behavior, which are usually delayed by minutes to hours, corticosteroid hormones also initiate rapid effects through diverse nongenomic mechanisms. One such mechanism involves the direct inhibition by corticosteroid hormones of monoamine transport mediated by the "uptake₂" transporter, organic cation transporter 3 (OCT3), a high-capacity, low-affinity transporter for norepinephrine, epinephrine, dopamine, serotonin, and histamine. In this review we describe studies that demonstrate OCT3 expression and corticosterone-sensitive monoamine transport in the brain and present evidence supporting the hypothesis that corticosterone exerts rapid, nongenomic actions on glia and neurons, ultimately modulating physiology and behavior, by inhibiting OCT3-mediated monoamine clearance. We also describe the corticosteroid sensitivity of the other members of the uptake₂ family and examine their potential contributions to nongenomic effects of corticosteroids in the brain.

Effect of concurrent organic cation transporter blockade on norepinephrine clearance inhibiting- and antidepressant-like actions of desipramine and venlafaxine

Depression is a major health problem for which most patients are not effectively treated. This underscores a need to identify new targets for the development of antidepressants with improved efficacy. Studies have shown that blockade of low-affinity/high-capacity transporters, such as organic cation transporters (OCTs) and the plasma membrane monoamine transporter (PMAT), with decynium-22 can produce antidepressant-like effects and inhibit serotonin clearance in brain when the serotonin transporter is pharmacologically or genetically compromised. In vitro studies show that OCTs/PMAT are also capable of norepinephrine transport, raising the possibility that decynium-22 might enhance the antidepressant-like effects of norepinephrine transporter inhibitors. Using in vivo electrochemistry, we show that local administration of decynium-22 into dentate gyrus of hippocampus enhanced the ability of the norepinephrine transporter blocker, desipramine, but not the dual norepinephrine/serotonin transporter blocker venlafaxine, to inhibit norepinephrine clearance. In parallel, systemic administration of decynium-22 (0.32 mg/kg) enhanced the antidepressant-like effects of desipramine (32 mg/kg), but not those of venlafaxine, in the tail suspension test, underscoring the heterogeneous response of mice to antidepressants, including those that share similar mechanisms of action. Systemic administration of normetanephrine, a potent blocker of OCT3, failed to potentiate the antidepressant-like effects of desipramine, suggesting that the actions of decynium-22 to augment the antidepressant-like effects of desipramine are likely mediated by another OCT isoform and/or PMAT. Taken together with existing literature, concurrent blockade of OCTs and/or PMAT merits further investigation as an adjunctive therapeutic for desipramine-like antidepressant drugs.

The brain in flux: Genetic, physiologic, and therapeutic perspectives on transporters in the CNS

The brain has specific properties that make it uniquely dependent upon transporters. This is the 3rd edition of a biennial special issue that originates from a scientific meeting devoted to studies of transporters and their relationship to brain function and to neurodevelopmental, neurologic, and psychiatric disorders. The field continues to rapidly evolve with advances in studies of structure that inform mechanism, with genetic analyses in humans revealing surprising aspects of biology, and with integrated cellular to whole animal analyses of the role of transporters in their control of physiology and pathophysiology. This special issue includes a sampling of review articles that address timely questions of the field followed by several primary research articles.

Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior

Contribution to Special Issue on Fast effects of steroids. Corticosteroid hormones act at intracellular glucocorticoid receptors (GR) and mineralocorticoid receptors (MR) to alter gene expression, leading to diverse physiological and behavioral responses. In addition to these classical genomic effects, corticosteroid hormones also exert rapid actions on physiology and behavior through a variety of non-genomic mechanisms, some of which involve GR or MR, and others of which are independent of these receptors. One such GR-independent mechanism involves corticosteroid-induced inhibition of monoamine transport mediated by "uptake₂" transporters, including organic cation transporter 3 (OCT3), a low-affinity, high-capacity transporter for norepinephrine, epinephrine, dopamine, serotonin and histamine. Corticosterone directly and acutely inhibits OCT3-mediated transport. This review describes the studies that initially characterized uptake₂ processes in peripheral tissues, and outlines studies that demonstrated OCT3 expression and corticosterone-sensitive monoamine transport in the brain. Evidence is presented supporting the hypothesis that corticosterone can exert rapid, GR-independent actions on neuronal physiology and behavior by inhibiting OCT3-mediated monoamine clearance. Implications of this mechanism for glucocorticoid-monoamine interactions in the context-dependent regulation of behavior are discussed.

Roles for the uptake2 transporter OCT3 in regulation of dopaminergic neurotransmission and behavior

Transporter-mediated uptake determines the peak concentration, duration, and physical spread of released monoamines. Most studies of monoamine clearance focus on the presynaptic uptake₁ transporters SERT, NET and DAT. However, recent studies have demonstrated the expression of the uptake₂ transporter OCT3 (organic cation transporter 3), throughout the rodent brain. In contrast to NET, DAT and SERT, OCT3 has higher capacity and lower affinity for substrates, is sodium-independent, and is multi-specific, with the capacity to transport norepinephrine, dopamine, serotonin and histamine. OCT3 is insensitive to inhibition by cocaine and antidepressant drugs but is inhibited directly by the glucocorticoid hormone corticosterone. Thus, OCT3 represents a novel, stress hormone-sensitive, monoamine transport mechanism. Incorporating this transporter into current models of monoaminergic neurotransmission requires information on: A) the cellular and subcellular localization of the transporter; B) the effects of OCT3 inhibitors on monoamine clearance; and C) the consequences of decreased OCT3-mediated transport on physiology and/or behavior. This review summarizes studies describing the anatomical distribution of OCT3, its cellular and subcellular localization, its contribution to the regulation of dopaminergic signaling, and its roles in the regulation of behavior. Together, these and other studies suggest that both Uptake₁ and Uptake₂ transporters play key roles in regulating monoaminergic neurotransmission and the effects of monoamines on behavior.

Decreased anxiety in mice lacking the organic cation transporter 3

The organic cation transporter 3 (OCT3; synonymous: extraneuronal monoamine transporter, EMT, Slc22a3) encodes an isoform of the organic cation transporters and is expressed widely across the whole brain. OCTs are a family of high-capacity, bidirectional, multispecific transporters of organic cations. These also include serotonin, dopamine and norepinephrine making OCTs attractive candidates for a variety of neuropsychiatric disorders including anxiety disorders. OCT3 has been implicated in termination of monoaminergic signalling in the central nervous system. Interestingly, OCT3 mRNA is however also significantly up-regulated in the hippocampus of serotonin transporter knockout mice where it might serve as an alternative reuptake mechanism for serotonin. The examination of the behavioural phenotype of OCT3 knockout mice thus is paramount to assess the role of OCT3. We have therefore subjected mice lacking the OCT3 gene to a comprehensive behavioural test battery. While cognitive functioning in the Morris water maze test and aggression levels measured with the resident-intruder paradigm were in the same range as the respective control animals, OCT3 knockout animals showed a tendency of increased activity and were significantly less anxious in the elevated plus-maze test and the open field test as compared to their respective wild-type controls arguing for a role of OCT3 in the regulation of fear and anxiety, probably by modulating the serotonergic tone in limbic circuitries.

Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine

Two distinct norepinephrine (NE) transporter mechanisms (uptake 1 and uptake 2) regulate extracellular NE concentrations. An association has been observed between the gradual improvement in patients treated with antidepressants that inhibit the NE transporter (NET/uptake 1) and increases in urinary normetanephrine, the O-methylated NE metabolite and potent inhibitor of uptake 2. These observations led to the hypothesis that increased levels of normetanephrine, and consequently inhibition of uptake 2, may partly be responsible for the clinical efficacy of some antidepressants. To investigate this hypothesis, we employed microdialysis techniques in the rat frontal cortex to monitor extracellular changes in normetanephrine following chronic administration of the clinically effective antidepressant, venlafaxine (a serotonin (5-HT) and NE reuptake inhibitor). We evaluated the neurochemical effects of inhibiting uptake 2 alone, or in conjunction with venlafaxine, on extracellular levels of NE and 5-HT. Chronic venlafaxine administration (14 days, 10 mg/kg, s.c.) elicited significant increases in cortical NE and 5-HT while producing a non-significant trend to increase cortical levels of normetanephrine. Additional studies revealed that combining normetanephrine with venlafaxine (10 mg/kg, i.p.), at a dose of normetanephrine (10 mg/kg, i.p.) that did not produce changes in extracellular levels of NE on its own, potentiated antidepressant-induced increases in extracellular NE. We also report mouse behavioral data involving the tail suspension test that complement the neurochemical observations. These preclinical findings, taken together, suggest that inhibiting both uptake 1 and uptake 2 via venlafaxine and normetanephrine, respectively, elicits a greater increase in cortical levels of NE than inhibiting either transporter alone.

The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process. 1964

In previous studies of the uptake of catechol amines in the rat isolated heart it was shown that adrenaline and noradrenaline were accumulated by a common mechanism (Iversen, 1963, 1965). In these experiments the uptake saturated at an external amine concentration of approximately 0.2 μg/ml. noradrenaline or 0.5 μg/ml. adrenaline. However, in subsequent experiments in which hearts were perfused with (±)-adrenaline at a concentration of 5.0 μg/ml. an unexpectedly large uptake of adrenaline was observed. This fortuitous observation led to an examination of the uptake of adrenaline and noradrenaline during perfusions at higher concentrations of each amine than had previously been studied.

The results of these experiments led to the conclusion that a second type of uptake operates at high perfusion concentrations. The properties of this second process are sufficiently different from those described previously to justify a clear-cut distinction between the two processes.

Simultaneous determination of plasma noradrenaline and adrenaline kinetics. Responses to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit

Liquid chromatographic fractionation and detection of exogenous radiolabelled and endogenous catechols was used to examine simultaneously the plasma kinetics of noradrenaline and adrenaline in the conscious rabbit. Plasma clearances and release of noradrenaline and adrenaline into plasma were compared before and during nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia, stimuli purported to differentially affect catecholamine release from sympathetic neurons and the adrenal medulla. Plasma concentrations of dihydroxyphenylglycol (DHPG) were also measured to assess presynaptic sympathetic function. Plasma clearances of adrenaline correlated with, but were significantly less than those of noradrenaline. Plasma clearances of both catecholamines showed significant decreases during nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia. Glucopenia and hypotension increased the release into plasma of noradrenaline and adrenaline, but the adrenaline response relative to the noradrenaline response was greater during glucopenia than during hypotension. Plasma DHPG concentrations increased during glucopenia and hypotension, consistent with increased neuronal reuptake of noradrenaline and therefore a neuronal source--as opposed to an adrenal source--of most of the noradrenaline appearing in plasma during the stimuli. The increase in plasma DHPG relative to that of noradrenaline was greater after 2-deoxyglucose than after nitroprusside suggesting that the presynaptic handling of noradrenaline during glucopenia was different from that during hypotension or that the two stimuli released DHPG from regionally distinct sources.

The uptake and metabolism of 5-hydroxytryptamine by tissue slices of the cestode Hymenolepis diminuta

The in vitro uptake of [3H]5HT was investigated in tissue slices of the cestode Hymenolepis diminuta. A concentrative, sodium sensitive, high affinity uptake mechanism (Km 1.43 X 10(-6) M; Vmax 222 fmoles/mg wet wt/min), together with a sodium insensitive component (linear up to 5 X 10(-6) M) were present. In the presence of 2-nitroimipramine the sodium sensitive component was significantly suppressed (Vmax 33 fmoles/mg/wet wt/min) although the Km (1.37 X 10(-6) M) was not affected. Nitroimipramine showed an IC50 of approximately 2 X 10(-6) M. The sodium insensitive component was not affected by nitroimipramine. Biogenic amines and related indoleamines were weak inhibitors of the sodium sensitive and sodium insensitive components of 5HT uptake. The tricyclic antidepressants and fluoxetine were effective inhibitors of the sodium sensitive component of 5-HT uptake; receptor ligands were weak inhibitors or without effect. The metabolism of [3H]5HT in tissue slices of H. diminuta was examined by HPLC. The role of the sodium sensitive uptake and metabolism of 5HT in terms of inactivation and recycling of neurally released 5HT and the possible importance of exogenous recruitment of 5HT are discussed.

Biochemical characterization of [3H]norepinephrine uptake in dissociated brain cell cultures from chick embryos

The uptake of [3H]norepinephrine ([3H]NE) was studied in dissociated brain cell cultures prepared from 8-day-old chick embryos using the whole brain (minus optic lobes). Uptake [3H]NE, 5 x 10(-9) m, 10 min incubation, in freshly dissociated noncultured embryonic chick brain cells, was detected in 6-day-old embryos; it was temperature and drug (cocaine, metanephrine) sensitive and increased with brain development. In cultured cells, which were assayed at various days in culture, the increase in [3H]NE accumulation per culture was less than that seen in freshly dissociated noncultured embryonic cells. When [H]NE uptake was expressed per mg protein, a decrease with days in culture was observed. reflecting perhaps a dilution of growth or proliferation of cells not accumulating NE. Metanephrine, 5 X 10(-6) M, an inhibitor of extraneuronal uptake, inhibited [3H]NE in 5-day-old cultures whereas desmethylimipramine, an inhibitor of neuronal uptake, inhibited [3H]NE uptake in 15- and 20-day-old cultures. Cocaine, another neuronal inhibitor, inhibited [3N]NE at 10 and 15 days only. We interpret these findings to suggest that during early growth in culture most neuroblasts accumulate NE nonspecifically and, as neuronal maturation proceeds, NE accumulation becomes specific.

Uptake and metabolism of catecholamines in the perfused hearts of different species

1. The uptake of (+/-)-(3)H-noradrenaline was studied in isolated perfused hearts of rat, mouse, guinea-pig, pigeon and toad (Bufo marinus), and the IC50 (concentration causing 50% inhibition) values for inhibition of uptake of (+/-)-(3)H-noradrenaline by (-)-noradrenaline were calculated. IC50 values ranging from 0.28 muM (rat heart) to 2.34 muM (toad heart) were found.2. In all species except the toad, (-)-noradrenaline showed a higher affinity than (-)-adrenaline for the uptake process, but the reverse was found for the toad heart.3. Mouse and pigeon hearts contained increasing amounts of metabolites of noradrenaline with increasing perfusion concentrations of noradrenaline, but the guinea-pig and toad hearts did not. The in vitro activities of noradrenaline catabolizing enzymes in heart homogenates were measured but did not explain the differences in the pattern of catabolism of noradrenaline found in the intact hearts of the different species.4. In all hearts except the toad, cocaine was an effective blocking agent for the uptake of (+/-)-(3)H-noradrenaline and led to an increase in (3)H-normetanephrine in these hearts. In the pigeon heart, cocaine plus phenoxybenzamine in the perfusate resulted in an inhibition of both (3)H-noradrenaline uptake and (3)H-normetanephrine formation.5. In guinea-pig and pigeon perfused hearts, the uptake of (3)H-noradrenaline into atria and ventricles reflected the relative concentrations of endogenous catecholamines in these regions, but this was not found for rat, mouse and toad hearts.6. It was concluded that species differences exist for both the accumulation and metabolism of catecholamines in isolated perfused hearts.

The extraneuronal uptake and localization of noradrenaline in the cat spleen and the effect on this of some drugs, of cold and of denervation

1. Extraneuronal uptake of noradrenaline (NA) was examined in the cat spleen first by perfusing with NA for 10 min, followed by a 2-min wash to clear the extracellular fluid, then measuring the amount retained, its subcellular distribution and the tissue components involved as revealed by the development of the characteristic fluorescence. Secondly, thin spleen slices were exposed to NA in vitro and the development of fluorescence in various structures, particularly arterial smooth muscle, measured.2. The cat spleen accumulated large quantities of NA and this, like the development of fluorescence, was concentration-dependent. After particle separation most of the retained amine appeared in the high-speed supernatant, with a lesser amount in the coarse granule fraction. There was little amine in either the mitochondrial or microsomal fraction. The microsomal fraction from unperfused spleens was rich in NA, presumably from storage granules from the adrenergic nerves. On an intermittent sucrose density gradient the NA-rich particles sedimented between 1.0 and 1.5 M sucrose, corresponding to the recently described dense granules from bovine splenic nerves.3. Fluorescence histochemistry revealed several tissues accumulating NA. At an NA concentration of 10(-5) g/ml., arterial smooth muscle and endothelium showed intracellular fluorescence; at 10(-4) g/ml., collagen, the perimeter of the smooth muscle cells of the capsule-trabecula-vein system and the reticular cells forming the framework of the spleen developed fluorescence. In the reticular cells the fluorescence was intracellular. The fluorescence pattern on the perimeter of non-arterial smooth muscle corresponded to the pattern of basement membrane as shown by PAS staining. The red pulp, lymphoid tissue and the phagocytic cells of the ellipsoids did not fluoresce.4. Cooling the tissue to 15 degrees C or less, phenoxybenzamine in a concentration of 5 x 10(-5) g/ml. or normetanephrine in a concentration of 10(-4) g/ml. prevented both uptake and loss of NA in arterial smooth muscle but had no effect on collagen.5. Chronic post-ganglionic denervation or reserpine had no effect on the development of fluorescence in any extraneuronal tissue.

The inhibition of human platelet 5-hydroxytryptamine uptake by tricyclic antidepressive drugs. The relation between structure and potency

Thirty-five compounds related to the antidepressive drug imipramine in chemical structure have been examined for their capacity to inhibit the uptake of 5-hydroxytryptamine by human platelets in vitro. Substitution by small-sized electropositive groups in positions 2 or 3 of a benzene ring gave compounds more active than the prototype, 3-chloroimipramine being five times as potent on this test. Alteration of the characteristic seven-membered ring of the antidepressive drugs reduced the activity while substitution in the basic side-chain destroyed it. The tertiary amines were more potent inhibitors than their demethylated derivatives. In this and other ways the active structure for the inhibition of 5-ht uptake by human blood platelets differs from that for the inhibition of noradrenaline uptake by the rat heart.

Effect of desipramine on directly or indirectly elicited catecholamine pressor responses in rats

Desipramine enhances the pressor effect induced by noradrenaline, adrenaline, dopamine and dimethylphenylpiperazinium in pithed rats, while indirectly acting sympathomimetic amines, such as tyramine and phenethylamine were inhibited. With a similar degree of noradrenaline potentiation, desipramine was more effective than cocaine as an inhibitor of the tyramine pressor response. Desipramine, but not cocaine, was effective in blocking the hypertension induced by small doses of reserpine in animals pretreated with tranylcypromine.